Skip to Content

Aspirin Tablets (Buffered)

Last Updated: October 21, 2014
Status: Resolved

Products Affected - Description

Products Affected - Description
Ascriptin Tablets, Novartis Consumer Health
325 mg tablets, 100 count (NDC 00067-0149-10)

Reason for the Shortage

  • Novartis has temporarily suspended manufacture of multiple drug products that were manufactured at the Lincoln facility including Bufferin and Ascriptin Tablets.
  • Novartis voluntarily recalled all lots of Bufferin Tablets with expiration dates of December 20, 2013 or earlier.
  • Novartis divested the rights for all Bufferin products to Ducere Pharma in early-2013.
  • Ducere Pharma re-introduced Bufferin tablets in late 2013.
  • Medique Products discontinued their buffered aspirin presentations in May, 2012.
  • Major states the shortage was due to increased demand for the product.
  • Teva discontinued their buffered aspirin products late 2009 and early 2010.

Available Products

Aspirin Tri-Buffered Tablets, Major
325 mg tablets, 100 count (NDC 00904-2015-59)

 
Bufferin Tablets, Ducere Pharma
325 mg tablets, 130 count (NDC 55741-0013-13)

Estimated Resupply Dates

All marketed presentations are available.

Related Shortages

Updated

October 21, 2014; August 4, 2014; May 29, 2014; March 27, 2014; January 29, 2014; November 21, 2013; September 19, 2013; July 12, 2013; May 6, 2013; March 8, 2013; January 4, 2013; December 19, 2012; October 31, 2012; September 5, 2012; July 31, 2012, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.

Hide